We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pico-Salax Colonic Preparation Study: Quantifying Electrolyte and Volume Status Changes

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00885430
First Posted: April 22, 2009
Last Update Posted: September 22, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Ferring Pharmaceuticals
Information provided by (Responsible Party):
Dr. Lawrence Hookey, Queen's University
April 20, 2009
April 22, 2009
September 22, 2015
July 2008
July 2008   (Final data collection date for primary outcome measure)
  • serum electrolytes [ Time Frame: 48 hours ]
  • patient hemodynamics [ Time Frame: 48 hours ]
Same as current
Complete list of historical versions of study NCT00885430 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Pico-Salax Colonic Preparation Study: Quantifying Electrolyte and Volume Status Changes
Pico-Salax Colonic Preparation Study: Quantifying Electrolyte and Volume Status Changes
Twenty adult volunteers will be administered Pico-Salax in the usual fashion for colonoscopy with intense monitoring of serum and urine chemistry and hemodynamics.
Not Provided
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
  • Hemodynamics
  • Hyponatremia
Drug: Pico-Salax
Two sachets of Pico-Salax given 5 hours apart
Experimental: Pico-Salax
Intervention: Drug: Pico-Salax
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
September 2008
July 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • healthy volunteers older than 45

Exclusion Criteria:

  • impaired renal function
  • congestive heart failure ascites known electrolyte abnormalities
Sexes Eligible for Study: All
45 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00885430
Hookey Pico-Salax Volunteers
No
Not Provided
Not Provided
Dr. Lawrence Hookey, Queen's University
Queen's University
Ferring Pharmaceuticals
Principal Investigator: Lawrence Hookey, MD Queen's University
Queen's University
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP